Merck & Co. plans to target hard-to-treat hepatitis C patients with its cure for the liver ailment rather than compete for market share by drastically undercutting the price of Gilead Sciences Inc.’s $1,000-a-day treatment.
Merck said Tuesday that the U.S. Food and Drug Administration accepted its application for approval of the single pill, which combines the medications grazoprevir and elbasvir, and granted the medicine a priority review. That means Merck is on course to introduce the treatment to the market early next year.
The field for hepatitis C patients is currently divided between AbbVie Inc. and Gilead, which have locked up arrangements with the leading managers of drug coverage in U.S. health insurance plans, ensuring their medications are the first choice. Still, Merck doesn’t foresee trouble attracting patients.
Read more...
Showing posts with label hard-to-treat. Show all posts
Showing posts with label hard-to-treat. Show all posts
Wednesday, July 29, 2015
Tuesday, June 9, 2015
Curing Hard-to-Treat Hepatitis C
In a new video, NIH researchers and their colleagues from health centers in the District of Columbia discuss efforts to improve treatments for hepatitis C, a potentially life-threatening viral disease that slowly damages the liver. NIH-sponsored clinical studies in the nation’s capital focus on identifying effective, safe, and convenient therapies for hard-to-treat hepatitis C patients, such as those who also have HIV.
Subscribe to:
Posts (Atom)